Document is current

Article History

Received: 5 November 2025

Accepted: 23 January 2026

First Online: 22 February 2026

Declarations

:

: Yoana Ivanova Markova and Mathilde Daheron are employed by Weber España, a company that received funding from UCB to conduct this study. Javier Bellas is an employee of UCB. Eva Vilarrasa, Joaquín Borrás Blasco, Silvia Lobo Benito, Marta Loro Pérez, Marta García Núñez-García, Juan Oliva Moreno, David Palacios Martínez, Félix Rubial Bernárdez, and Antonio Martorell received fees from UCB for their expert advice during study conduction. Eva Vilarrasa has received funding and/or honoraria for educational activities, consultancy, advisory roles, or speaking engagements from Abbvie, Aceleryn, Almirall, Amgen, Bayer, Biofrontera, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Galderma, Gebro, Incyte, Isdin, Johnson and Johnson, Leo Pharma, Lilly, Merck-Serono, MoonLake, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, and UCB. She has also worked as a consultant, investigator, or collaborator with the following companies and startups: iDermApp, Mediktor, DermUS, Biomi, and Barcelona Health Hub. Eva Vilarrasa is an Editorial Board member of Dermatology and Therapy. Eva Vilarrasa was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Joaquín Borrás Blasco has received funding and/or honoraria for educational activities, consultancy, research, or speaking engagements at events of medical and scientific interest from Boehringer Ingelheim, Johnson and Johnson, Pfizer, Sanofi, and UCB. Antonio Martorell has received honoraria and/or travel grants and/or has served as a member of advisory committees for Abbvie, Aceleryn, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Incyte, Johnson and Johnson, Leo Pharma, MoonLake, Novartis, Pfizer, Sandoz, Sanofi, UCB, and Legit Health. He has also served as a principal investigator in clinical trials sponsored by Abbvie, Aceleryn, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Incyte, Johnson and Johnson, Leo Pharma, MoonLake, Novartis, Pfizer, MSD, Takeda, Sanofi, UCB, and MSD. Marta Loro Pérez has received financial support for collaborative research projects or and/or consultancy honoraria from Janssen-Cilag, Pzfizer, Novartis, Abbvie and UCB. Juan Oliva Moreno, Silvia Lobo Benito, Marta García Núñez-García, David Palacios Martínez and Félix Rubial Bernárdez do not declare any conflicts of interest.

: No ethical approval was required for this study, as the data were obtained from previously approved studies/registries. Data sourced from the AvanceHS survey were analyzed in anonymized form.